The global oncology flow cytometry market is


New York, June 09, 2021 (GLOBE NEWSWIRE) – Reportlinker.com announces the publication of the report “Global Flow Cytometry in Oncology Market: Focus on Product Type, Technology, Type of Cancer, Applications, End Users, Country Data (16 Countries) and Competitive Landscape – Analysis and Forecast, 2021-2031 “- https://www.reportlinker.com/p06090602/?utm_source=GNW

• Product type – Assays and kits, instruments, reagents and consumables, and software
• Technology – cell based and bead based
• Type of cancer – Hematologic malignancies (lymphoma, leukemia, myeloma and other hematologic malignancies) and solid tumors (breast cancer, prostate cancer, colorectal cancer, lung cancer and other solid tumors)
• Application – Translational research and clinical applications (screening and diagnosis, and treatment monitoring)
• End user – Diagnostic laboratories, hospitals and health centers, academic and research institutions and other end users

Regional segmentation

• North America – United States and Canada
• Europe: Germany, United Kingdom, France, Italy, Spain, Netherlands and rest of Europe
• Asia-Pacific: China, Japan, India, Australia, South Korea, Singapore and rest of Asia-Pacific
• Latin America: Brazil, Mexico and the rest of Latin America
• Rest of the world

Market growth drivers

• Increased incidence of hematologic malignancies
• Increased infusions of funds for hematologic malignancies
• Growing consumer awareness of tailored therapy and precision medicine

Market challenges

• False negatives and positives
• Restricted specificity offered by conventional MRD assessment based on flow cytometry

Market opportunities

• Technological evolution in the field of flow cytometry
• Growth of solid tumor applications of flow cytometry

Profile of Major Surgical Instrument Tracking Device Companies

Agilent Technologies, Inc., Apogee Flow Systems Ltd., Becton, Dickinson and Company, bioAffinity Technologies, Inc., Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Cytek Biosciences, Cytognos, SL, Danaher Corporation, Miltenyi Biotec BV & Co. KG, Laboratory Corporation of America Holdings, Luminex Corporation, NeoGenomics Laboratories, Inc., Sony Corporation and Thermo Fisher Scientific Inc.

Key questions addressed in this report:
• How is flow cytometry revolutionizing the field of oncology?
• What are the key market drivers, challenges, and opportunities in the global oncology flow cytometry market?
• What are the underlying structures driving emerging trends in the global Oncology Flow Cytometry Market?
• What is the impact of the COVID-19 pandemic on global flow cytometry in the oncology ecosystem?
• What are the main development strategies that are implemented by the main players in order to support the competitive market?
• What are the main regulatory implications in developed and developing regions regarding the use of flow cytometry in oncology?
• What are the potential barriers to entry that businesses wishing to enter a particular region should face?

• How is each market segment expected to grow during the forecast period 2021-2031, and what are the expected revenue generated by each of the segments? Here are the segments:
o Product type (tests and kits, instruments, reagents and consumables, and software)
o Technology (cell-based and bead-based)
o Type of cancer (hematologic malignancies and solid tumor)
o Application (translational research and clinical applications)
o End user (diagnostic laboratories, hospitals and health clinics, academic and research institutes and other end users)
o Region (North America, Europe, Asia-Pacific, Latin America and rest of the world)
• What are the growth opportunities for companies in the region where they operate?
• Who are the main players offering significant offerings in the global oncology flow cytometry market?
• Which companies are expected to be very disruptive in the future, and why?

Market Snapshot

Our healthcare experts have discovered that flow cytometry in the oncology industry is one of the most dynamic and rapidly changing markets. The global oncology flow cytometry market is expected to grow at a CAGR of 12.02% during the forecast period 2021-2031. The market is driven by certain factors including the growing incidence of Hematologic Malignancies, increasing infusions of funds for Hematologic Malignancies, and increasing consumer awareness of tailor-made therapy and precision medicine.

The market is driven by developments in the field of diagnostic tests for cancer and its attributes such as flow cytometry. and growing consumer awareness for tailor-made therapy and precision medicine.

Moreover, the high adoption of flow cytometry instruments by end users to perform cancer diagnosis and therapeutic monitoring are some of the critical factors that are expected to support the market growth.

In addition, biotechnology companies are focused on developing robust flow cytometry solutions for a wide range of applications, including translational research and clinical applications, to help researchers and physicians unravel knowledge. relating to cellular alterations.

In the research report, the market is segmented on the basis of product type, technology, cancer type, application, end-users, and region. Each of these segments covers the market snapshot over the projected years, market revenue tilt, underlying patterns and trends using analyzes on the obtained primary and secondary data.

Competitive landscape

The exponential increase in the number of cases associated with cancer, especially hematologic malignancies, has created a buzz among biotech companies to invest more in the development of cancer diagnostic solutions such as flow cytometry, further assisting physicians to deliver therapeutic outcomes based on patient value. Becton, Dickinson and Company has been a pioneer in this field and has been a significant competitor in this market due to the presence of a diverse product portfolio and intense market penetration.

Based on region, in 2020, North America held the largest share of the oncology flow cytometry market due to the high injection of funding from government organizations for cancer research, the ‘increasing incidence and prevalence of cancer, increasing awareness of precision medicine, and increasing awareness of early detection of cancer, among others. Apart from this, the Asia-Pacific region is expected to grow at the fastest CAGR during the forecast period 2021-2031.

Covered countries
• North America
• US
• Canada
• Europe
• Germany
• Italy
• France
• Spain
• UK
• Netherlands
• The rest of Europe
• Asia Pacific
• China
• Japan
• India
• South Korea
• Australia
• Singapore
• Rest of Asia-Pacific
• Latin America
• Brazil
• Mexico
• Rest of Latin America
• Rest of the world
Read the full report: https://www.reportlinker.com/p06090602/?utm_source=GNW

About Reportlinker
ReportLinker is an award winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.

__________________________



About Hector Hedgepeth

Check Also

Oxford BioDynamics Checkpoint Inhibitor Response Test (EpiSwitch® CiRT) Now Available in the UK

Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for …

Leave a Reply

Your email address will not be published.